Treatment of Childhood Nasopharyngeal Carcinoma with Neoadjuvant Chemotherapy and Concomitant Chemoradiotherapy

In order for our site to display correctly you will need a newer version of your web browser.

Currently we test and support the following browsers:

FireFox version 3.0 and above (Windows and Mac)
Safari version 5.0 and above (Windows and Mac)
Internet Explorer version 7.0 and above (Windows)

Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.

Research

Protocol

RAR331: Treatment of Childhood Nasopharyngeal Carcinoma with Neoadjuvant Chemotherapy and Concomitant Chemoradiotherapy

Diseases

Solid Tumor : Nasopharyngeal carcinoma

Description

Nasopharyngeal carcinoma is very rare in children. The nasopharynx is located in the upper part of the throat behind the nose. Air passes through it to the lungs and food passes through it as it is swallowed. An opening on each side of the nasopharynx leads in to an ear.

Because of the location of nasopharyngeal carcinoma, the tumor usually cannot be totally removed with surgery. When patients are diagnosed early and the tumor is small, the treatment is usually radiation therapy only. Patients with more advanced disease usually get chemotherapy and radiation therapy. These patients commonly have larger tumors, or cancer that has spread to the lymph nodes of the neck.

This study will involve the use of radiation therapy, chemotherapy, and chemoradiotherapy. Radiation therapy involves the use of high-energy x-rays or other types of radiation to kill cancer cells. Chemotherapy is the use of anti-cancer drugs to stop the growth of cancer cells. Chemoradiotherapy is chemotherapy given at the same time as radiation therapy.

Objectives

To determine if the combination of chemotherapy followed by chemoradiotherapy works better at treating children with advanced nasopharyngeal carcinoma

Eligibility

Patient has nasopharyngeal carcinoma which was diagnosed prior to the patient being 19 years of age
Patient meets defined requirements for the ability to perform ordinary tasks and daily activities
Patient has adequate function of the liver and kidney

For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children's Research Hospital at 1-866-2ST-JUDE (1-866-278-5833).

Contact

Wayne Furman, MD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Voice: 1-888-226-4343 or 901-595-4055
Fax: 901-595-4011

Referring or consulting physicians only: protocolinfo@stjude.org

For all other inquiries about St. Jude Children's Research Hospital studies: info@stjude.org

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.

Print Email This Article